Savolitinib combine with Durvalumab in EGFR wild-type locally advanced or metastatic NSCLC - SOUND

Study identifier:D5083C00002

ClinicalTrials.gov identifier:NCT05374603

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

Savolitinib combine with Durvalumab in Chinese EGFR wild-type locally advanced or metastatic NSCLC patients with MET alteration: An open-label, interventional, multiple-center, exploratory trial (SOUND)

Medical condition

lung cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

Savolitinib, Durvalumab

Sex

All

Actual Enrollment

47

Study type

Interventional

Age

n/a - n/a

Date

Study Start Date: 23 Nov 2022
Estimated Primary Completion Date: 30 Aug 2025
Estimated Study Completion Date: 30 Aug 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria